Tissue Regenix Completes Acquisition of CellRight Technologies

Tissue Regenix (TRX) completed its acquisition of CellRight Technologies. The purchase price was previously noted as US $30.0MM.

The transaction more than doubles TRX's U.S. sales and pairs complementary platforms of soft tissue regeneration with CellRight's regenerative osteoconductive bone scaffolds.

TRX plans to launch its OrthoPure™...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us